## Protocol Section
### Identification Module
**NCT ID:** NCT06422819

**Acronym:** HRV_BFB_FND

**Brief Title:** Clinical Evaluation of HRV Biofeedback in Functional Neurological Disorders Compared to Placebo

**Official Title:** Probing the Heart Rate Variability Biofeedback as an Innovative and Non-invasive Treatment for Functional Neurological Disorders Guided by a Multimodal Approach of Autonomic Nervous System.

#### Organization Study ID Info
**ID:** 2024-12156
#### Organization
**Class:** OTHER
**Full Name:** Centre hospitalier de l'Université de Montréal (CHUM)
### Status Module
#### Completion Date
**Date:** 2027-05

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-21

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-15

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2027-05

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-06

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-21
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-15
**Study First Submit QC Date:** 2024-05-15
### Sponsor Collaborators Module

#### Collaborators

**Class:** OTHER

**Name:** Laboratoire de Psychologie et NeuroCognition

#### Lead Sponsor

**Class:** OTHER

**Name:** Centre hospitalier de l'Université de Montréal (CHUM)

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** False

### Description Module

**Brief Summary:** Evaluation of the clinical effects of the Heart Rate Variability biofeedback training with patients suffering from Functional neurological Disorders compared with placebo.

**Detailed Description:** Although Functional Neurological Disorders (FND) represent one of the most common reasons for consultation in Neurology, the pathological mechanisms remain unexplained. Recent studies suggest disrupted emotional processes in patients with FND and disturbed autonomic nervous system profiles, highligting the hypothesis of autonomic endophenotypes among the FND population.

The Heart Rate Variability Biofeedback (HRV-BFB) is an innovative and non-invasive approach, based on the self-regulation of autonomic physiological processes. It has shown promising results in clinical and non-clinical populations but has never been assessed in an adult FND population.

Therefore, this approach appears particularly promising for understanding the mechanisms underlying FND and developing personalized therapy.

The main objective is to investigate the clinical effects of HRV-BFB on FND patients compared to placebo in a single-blind crossover design.

The investigators predict that depending on their autonomic profile, patients will respond to HRV-BFB to varying degrees.

Firstly, patients with FND will prospectively undergo an comprehensive clinical evaluation considering symptoms, functional capacity, quality of life, and an assessment of the physical and psychological comorbidities. Then patients will complete an emotional task and undergo multimodal autonomic measures. Cluster analyses will be conducted to identify both dysfunctional and functional autonomic profiles associated with the clinical exploration, enabling confirmation of the endophenotypes hypothesis and allowing for specific characterization of the profils. The clinical evaluation of the beneficial effects of HRV BFB will rely on repeated mesures of symptoms, functional capacity, and quality of life at scheduled points in time before and after the both interventions (HRV-BFB and pseudo-BFB). The emotional task and autonomic measures will be repeated simultaneously.

### Conditions Module

**Conditions:**

- Functional Neurological Disorder

**Keywords:**

- Functional Neurological Disorder

- Emotional dysregulation

- Autonomic nervous system

- Endophenotypes

- Biofeedback of Heart Rate Variability

- Transdiagnostic approach

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** CROSSOVER

**Intervention Model Description:** This study consists of 5 visits (V1, V2, V3, V4, V5). At V1, participants will be randomized into two groups: HRV-BFB (experimental group) or Pseudo HRV-BFB (control group). Participants will remain single-blinded after randomization. Depending on the assigned group, participants will practice one specific intervention during the first 30-day period (V1-V2). At V2, participants will switch to the other arm and practice the second intervention during the second 30-day period (V2-V3). At V3, both interventions will end, and participants will be unblinded and encouraged to continue HRV-BFB at home. Clinical evaluation will be repeated 5 times at day 1 (V1), days 30 +/- 10 (V2), days 60 +/- 10 (V2), 6 months (V4) and 1 year (V5). The research team will exercise extreme caution to ensure consistent instructions and feedback, minimizing biases associated with lack of double-blinding.

##### Masking Info

**Masking:** SINGLE

**Masking Description:** The participants won't be informed of the condition to which they belong. A debriefing will be done at the end of the last intervention (V3) for each participant.

**Who Masked:**

- PARTICIPANT

**Primary Purpose:** SUPPORTIVE_CARE

#### Enrollment Info

**Count:** 31

**Type:** ESTIMATED

**Phases:**

- NA

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Description:** Participants assigned to the experimental group will undergo HRV Biofeedback training using the Inner Balance Coherence Plus® software. This software incorporates a Bluetooth plethysmograph ear sensor, which will transmit cardiac pulse data to the Inner Balance Coherence Plus smartphone app, where the EmWave Pro® Plus software will extract HRV in real-time. This software will display the participant's HRV-BFB curve on their smartphone. The installation of the program and necessary instructions for its use will be provided at the first visit (V1). Fractional training sessions of 8 minutes will be recommended, twice daily for 30 days (during the period V1-V2 or the period V2-V3). Respiratory instructions will differ between the two interventions. During the HRV-BFB intervention, participants will be instructed to maximize their HRV.

**Intervention Names:**

- Other: Heart rate variability Biofeedback [HRV-BFB]

**Label:** Experimental group (HRV-BFB training)

**Type:** EXPERIMENTAL

#### Arm Group 2

**Description:** Participants assigned to the placebo group will undergo a pseudo HRV Biofeedback training using the same Inner Balance Coherence Plus® software and ear sensor. The software will similarly display the participant's HRV-BFB curve on their smartphone. The installation of the program and necessary instructions for its use will be provided at the first visit (V1). To manage placebo effects, the same fractional training sessions of 8 minutes will be recommended, twice daily for 30 days (during the period V1-V2 or the period V2-V3). Respiratory instructions will differ between the two interventions. During the placebo pseudo BFB training, participants will be instructed to no have specific effect on HRV.

**Intervention Names:**

- Other: Pseudo HRV-BFB

**Label:** Placebo Control group (Pseudo HRV-BFB training)

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Experimental group (HRV-BFB training)

**Description:** Biofeedback (BFB), sometimes referred to as "biological feedback technique," is a non-invasive and non-pharmacological approach based on physiological recordings that provide real-time feedback enabling people to learn how to control their physiological processes, which are typically unconscious and beyond their control. HRV-BFB specifically targets heart rate variability (HRV), which can help regulate the autonomic nervous system (including vagal tone and sympathetic-parasympathetic balance) as well as emotional states. HRV-BFB has been clinically and experimentally validated as a physiological intervention and has demonstrated its effectiveness. However, it has never been studied in an adult FND population.

**Name:** Heart rate variability Biofeedback [HRV-BFB]

**Type:** OTHER

#### Intervention 2

**Arm Group Labels:**

- Placebo Control group (Pseudo HRV-BFB training)

**Description:** The pseudo HRV-BFB intervention aims to implement the same HRV BFB methods with no specific effect on HRV.

**Name:** Pseudo HRV-BFB

**Type:** OTHER

### Outcomes Module

#### Primary Outcomes

**Description:** The impression improvement and severity of the core symptoms will be measured by the participant using the Clinical Global Impression Improvement and/or Severity scale (CGI-I \& CGI-S; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Patient Clinical Global Impression Score

**Time Frame:** Day 1 (V1)

**Description:** The impression improvement and severity of the core symptoms will be measured by the participant using the Clinical Global Impression Improvement and/or Severity scale ( (CGI-I \& CGI-S; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Patient Clinical Global Impression Score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The impression improvement and severity of the core symptoms will be measured by the participant using the Clinical Global Impression Improvement and/or Severity scale ( (CGI-I \& CGI-S; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Patient Clinical Global Impression Score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The impression improvement and severity of the core symptoms will be measured by the participant using the Clinical Global Impression Improvement and/or Severity scale ( (CGI-I \& CGI-S; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Patient Clinical Global Impression Score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The impression improvement and severity of the core symptoms will be measured by the participant using the Clinical Global Impression Improvement and/or Severity scale ( (CGI-I \& CGI-S; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Patient Clinical Global Impression Score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The impression improvement and severity of the core symptoms will be measured by the clinician using the Clinical Global Impression Improvement and/or Severity scale (CGI; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Clinician Clinical Global Impression Score

**Time Frame:** Day 1 (V1)

**Description:** The impression improvement and severity of the core symptoms will be measured by the clinician using the Clinical Global Impression Improvement and/or Severity scale (CGI; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Clinician Clinical Global Impression Score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The impression improvement and severity of the core symptoms will be measured by the clinician using the Clinical Global Impression Improvement and/or Severity scale (CGI; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Clinician Clinical Global Impression Score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The impression improvement and severity of the core symptoms will be measured by the clinician using the Clinical Global Impression Improvement and/or Severity scale (CGI; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Clinician Clinical Global Impression Score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The impression improvement and severity of the core symptoms will be measured by the clinician using the Clinical Global Impression Improvement and/or Severity scale (CGI; French version Busner \& Targum, 2007). This scale includes 2 items.

**Measure:** Clinician Clinical Global Impression Score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Quality of life Score will be measured using the 36-Item Short Form Survey (SF-36; Jenkinson et al., 1993; French version Leplège et al., 1998). This scale includes 36 items.

**Measure:** Quality of life Score

**Time Frame:** Day 1 (V1)

**Description:** The Quality of life Score will be measured using the 36-Item Short Form Survey (SF-36; Jenkinson et al., 1993; French version Leplège et al., 1998). This scale includes 36 items.

**Measure:** Quality of life Score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Quality of life Score will be measured using the 36-Item Short Form Survey (SF-36; Jenkinson et al., 1993; French version Leplège et al., 1998). This scale includes 36 items.

**Measure:** Quality of life Score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Quality of life Score will be measured using the 36-Item Short Form Survey (SF-36; Jenkinson et al., 1993; French version Leplège et al., 1998). This scale includes 36 items.

**Measure:** Quality of life Score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Quality of life Score will be measured using the 36-Item Short Form Survey (SF-36; Jenkinson et al., 1993; French version Leplège et al., 1998). This scale includes 36 items.

**Measure:** Quality of life Score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Self-perception of Occupation will be measured using the Occupational Self- Assessment scale (OSA; French version Baron et al.,2006). This scale includes 21 items.

**Measure:** Self-perception of Occupation Score

**Time Frame:** Day 1 (V1)

**Description:** The Self-perception of Occupation will be measured using the Occupational Self- Assessment scale (OSA; French version Baron et al.,2006). This scale includes 21 items.

**Measure:** Self-perception of Occupation Score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Self-perception of Occupation will be measured using the Occupational Self- Assessment scale (OSA; French version Baron et al.,2006). This scale includes 21 items.

**Measure:** Self-perception of Occupation Score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Self-perception of Occupation will be measured using the Occupational Self- Assessment scale (OSA; French version Baron et al.,2006). This scale includes 21 items.

**Measure:** Self-perception of Occupation Score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Self-perception of Occupation will be measured using the Occupational Self- Assessment scale (OSA; French version Baron et al.,2006). This scale includes 21 items.

**Measure:** Self-perception of Occupation Score

**Time Frame:** Up to 360 days from V1 (V5)

#### Secondary Outcomes

**Description:** The other physical symptoms will be measured using the Patient Health Questionnaire (PHQ-15; French version Kroenke et al., 2002). This scale includes 15 items.

**Measure:** Other physical symptoms score

**Time Frame:** Day 1 (V1)

**Description:** The other physical symptoms will be measured using the Patient Health Questionnaire (PHQ-15; French version Kroenke et al., 2002). This scale includes 15 items.

**Measure:** Other physical symptoms score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The other physical symptoms will be measured using the Patient Health Questionnaire (PHQ-15; French version Kroenke et al., 2002). This scale includes 15 items.

**Measure:** Other physical symptoms score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The other physical symptoms will be measured using the Patient Health Questionnaire (PHQ-15; French version Kroenke et al., 2002). This scale includes 15 items.

**Measure:** Other physical symptoms score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The other physical symptoms will be measured using the Patient Health Questionnaire (PHQ-15; French version Kroenke et al., 2002). This scale includes 15 items.

**Measure:** Other physical symptoms score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Depressive symptoms score will be measured using the for Epidemiologic Studies-- Depression (CES-D; Radloff, 1977; French version Führer \& Rouillon, 1989). This scale includes 20 items.

**Measure:** Depressive symptoms score

**Time Frame:** Day 1 (V1)

**Description:** The Depressive symptoms score will be measured using the for Epidemiologic Studies-- Depression (CES-D; Radloff, 1977; French version Führer \& Rouillon, 1989). This scale includes 20 items.

**Measure:** Depressive symptoms score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Depressive symptoms score will be measured using the for Epidemiologic Studies-- Depression (CES-D; Radloff, 1977; French version Führer \& Rouillon, 1989). This scale includes 20 items.

**Measure:** Depressive symptoms score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Depressive symptoms score will be measured using the for Epidemiologic Studies-- Depression (CES-D; Radloff, 1977; French version Führer \& Rouillon, 1989). This scale includes 20 items.

**Measure:** Depressive symptoms score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Depressive symptoms score will be measured using the for Epidemiologic Studies-- Depression (CES-D; Radloff, 1977; French version Führer \& Rouillon, 1989). This scale includes 20 items.

**Measure:** Depressive symptoms score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Trait anxiety score will be measured using the Trait Anxiety Inventory (STAI- B; Spielberger, 1989; French version Bruchon-Schweitzer \& Paulhan, 1993; Huyghe Lydie, 2021). This scale includes 20 items.

**Measure:** Trait anxiety score

**Time Frame:** Day 1 (V1)

**Description:** The Trait anxiety score will be measured using the Trait Anxiety Inventory (STAI- B; Spielberger, 1989; French version Bruchon-Schweitzer \& Paulhan, 1993; Huyghe Lydie, 2021). This scale includes 20 items.

**Measure:** Trait anxiety score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Trait anxiety score will be measured using the Trait Anxiety Inventory (STAI- B; Spielberger, 1989; French version Bruchon-Schweitzer \& Paulhan, 1993; Huyghe Lydie, 2021). This scale includes 20 items.

**Measure:** Trait anxiety score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Trait anxiety score will be measured using the Trait Anxiety Inventory (STAI- B; Spielberger, 1989; French version Bruchon-Schweitzer \& Paulhan, 1993; Huyghe Lydie, 2021). This scale includes 20 items.

**Measure:** Trait anxiety score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Trait anxiety score will be measured using the Trait Anxiety Inventory (STAI- B; Spielberger, 1989; French version Bruchon-Schweitzer \& Paulhan, 1993; Huyghe Lydie, 2021). This scale includes 20 items.

**Measure:** Trait anxiety score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The quality of sleep will be measured using the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2002, French versionAit-Aoudia et al., 2013). This scale includes 7 items.

**Measure:** Quality of sleep measure

**Time Frame:** Day 1 (V1)

**Description:** The quality of sleep will be measured using the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2002, French versionAit-Aoudia et al., 2013). This scale includes 7 items.

**Measure:** Quality of sleep measure

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The quality of sleep measure will be measure using the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2002, French versionAit-Aoudia et al., 2013). This scale includes 7 items.

**Measure:** Quality of sleep measure

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The quality of sleep will be measured using the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2002, French versionAit-Aoudia et al., 2013). This scale includes 7 items.

**Measure:** Quality of sleep measure

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The quality of sleep will be measured using the Pittsburgh Sleep Quality Index (PSQI; Buysse et al., 2002, French versionAit-Aoudia et al., 2013). This scale includes 7 items.

**Measure:** Quality of sleep measure

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Dissociative Experiences will be measured using the Dissociative Experiences Scale EDS; Steinberg et al., 1991; french version Eve Bernstein Carlson et Frank W. Putnam, 1986). This scale includes 28 items.

**Measure:** Dissociative Experiences

**Time Frame:** Day 1 (V1)

**Description:** The Dissociative Experiences will be measured using the Dissociative Experiences Scale EDS; Steinberg et al., 1991; french version Eve Bernstein Carlson et Frank W. Putnam, 1986). This scale includes 28 items.

**Measure:** Dissociative Experiences

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Dissociative Experiences will be measured using the Dissociative Experiences Scale EDS; Steinberg et al., 1991; french version Eve Bernstein Carlson et Frank W. Putnam, 1986). This scale includes 28 items.

**Measure:** Dissociative Experiences

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Dissociative Experiences will be measured using the Dissociative Experiences Scale EDS; Steinberg et al., 1991; french version Eve Bernstein Carlson et Frank W. Putnam, 1986). This scale includes 28 items.

**Measure:** Dissociative Experiences

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Dissociative Experiences will be measured using the Dissociative Experiences Scale EDS; Steinberg et al., 1991; french version Eve Bernstein Carlson et Frank W. Putnam, 1986). This scale includes 28 items.

**Measure:** Dissociative Experiences

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** Alexithymia score will be measured using the Toronto Alexithymia Scale (TAS-20; French version Loas, 1996). This scale includes 20 items.

**Measure:** Alexithymia score

**Time Frame:** Day 1 (V1)

**Description:** Brief Illness Perception score will be measured using the Brief Illness Perception Questionnaire (B-IPQ) (Moss-Morris et al., 2002 ; French version Demoulin et al., 2015). This scale includes 9 items.

**Measure:** Brief Illness Perception score

**Time Frame:** Day 1 (V1)

**Description:** Brief Illness Perception score will be measured using the Brief Illness Perception Questionnaire (B-IPQ) (Moss-Morris et al., 2002 ; French version Demoulin et al., 2015). This scale includes 9 items.

**Measure:** Brief Illness Perception score

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Brief Illness Perception score will be measured using the Brief Illness Perception Questionnaire (B-IPQ) (Moss-Morris et al., 2002 ; French version Demoulin et al., 2015). This scale includes 9 items.

**Measure:** Brief Illness Perception score

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Brief Illness Perception score will be measured using the Brief Illness Perception Questionnaire (B-IPQ) (Moss-Morris et al., 2002 ; French version Demoulin et al., 2015). This scale includes 9 items.

**Measure:** Brief Illness Perception score

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** Brief Illness Perception score will be measured using the Brief Illness Perception Questionnaire (B-IPQ) (Moss-Morris et al., 2002 ; French version Demoulin et al., 2015). This scale includes 9 items.

**Measure:** Brief Illness Perception score

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Emotion Regulation Profile score will be measured using the Emotion Regulation Profile-Revised (ERP-R) (French version Nelis et al., 2011). This scale includes 15 items.

**Measure:** Emotion Regulation Profile

**Time Frame:** Day 1 (V1)

**Description:** The Emotion Regulation Profile score will be measured using the Emotion Regulation Profile-Revised (ERP-R) (French version Nelis et al., 2011). This scale includes 15 items.

**Measure:** Emotion Regulation Profile

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** The Emotion Regulation Profile score will be measured using the Emotion Regulation Profile-Revised (ERP-R) (French version Nelis et al., 2011). This scale includes 15 items.

**Measure:** Emotion Regulation Profile

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** The Emotion Regulation Profile score will be measured using the Emotion Regulation Profile-Revised (ERP-R) (French version Nelis et al., 2011). This scale includes 15 items.

**Measure:** Emotion Regulation Profile

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** The Emotion Regulation Profile score will be measured using the Emotion Regulation Profile-Revised (ERP-R) (French version Nelis et al., 2011). This scale includes 15 items.

**Measure:** Emotion Regulation Profile

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** The Childhood Trauma profile will be measured using the Childhood Trauma Questionnaire-Short Form (CTQ; Frenc version Paquette et al., 2004). This scale includes 28 items.

**Measure:** Childhood Trauma profile

**Time Frame:** Day 1 (V1)

**Description:** The Positive Affect and Negative Affects will be measured using the Positive Affect and Negative Affect Schedule (PANAS; Watson et al., 1988. French version Caci \& Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. This scale includes 20 items.

**Measure:** Positive Affect and Negative Affects

**Time Frame:** Day 1 (V1) before the emotional induction task

**Description:** The Positive Affect and Negative Affects will be measured using the Positive Affect and Negative Affect Schedule (PANAS; Watson et al., 1988. French version Caci \& Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. This scale includes 20 items.

**Measure:** Positive Affect and Negative Affects

**Time Frame:** Day 1 (V1) after the emotional induction task

**Description:** The Positive Affect and Negative Affects will be measured using the Positive Affect and Negative Affect Schedule (PANAS; Watson et al., 1988. French version Caci \& Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. This scale includes 20 items.

**Measure:** Positive Affect and Negative Affects

**Time Frame:** Up to 40 days from V1 (V2) before the emotional re-exposure task

**Description:** The Positive Affect and Negative Affects will be measured using the Positive Affect and Negative Affect Schedule (PANAS; Watson et al., 1988. French version Caci \& Bayle, 2007). To measure a global affective state, a score of positivity will be calculated by subtracting negative affect score from positive affect score. This scale includes 20 items.

**Measure:** Positive Affect and Negative Affects

**Time Frame:** Up to 40 days from V1 (V2) after the emotional re-exposure task

**Description:** High Frequency (\>0.15 Hz), frequency-domain parameter. HF will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** High Frequency [HF] (>0.15 Hz)

**Time Frame:** Day 1 (V1)

**Description:** High Frequency (\>0.15 Hz), frequency-domain parameter. HF will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** High Frequency [HF] (>0.15 Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** High Frequency (\>0.15 Hz), frequency-domain parameter. HF will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** High Frequency [HF] (>0.15 Hz)

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** High Frequency (\>0.15 Hz), frequency-domain parameter. HF will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** High Frequency [HF] (>0.15 Hz)

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** High Frequency (\>0.15 Hz), frequency-domain parameter. HF will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** High Frequency [HF] (>0.15 Hz)

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** Root Mean Square of Successive Differences, Frequency-domain parameter. RMSSD will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** Root Mean Square of Successive Differences [RMSSD]

**Time Frame:** Day 1 (V1)

**Description:** Root Mean Square of Successive Differences, Frequency-domain parameter. RMSSD will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** Root Mean Square of Successive Differences [RMSSD]

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Root Mean Square of Successive Differences, Frequency-domain parameter. RMSSD will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** Root Mean Square of Successive Differences [RMSSD]

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Root Mean Square of Successive Differences, Frequency-domain parameter. RMSSD will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** Root Mean Square of Successive Differences [RMSSD]

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** Root Mean Square of Successive Differences, Frequency-domain parameter. RMSSD will be measured using the electrocardiogram \[ECG\]: ECG data will be recorded using 3 single use and adhesive electrodes placed on the inner side of the right wrist, on the right shoulder and on the left side in accordance with the DII standard position (Einthoven). Physiological data recorded are related to the heart rate variability \[HRV\].

**Measure:** Root Mean Square of Successive Differences [RMSSD]

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** Skin conductance responses \[SCR\] frequency : number of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] frequency

**Time Frame:** Day 1 (V1)

**Description:** Skin conductance responses \[SCR\] frequency : number of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] frequency

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Skin conductance responses \[SCR\] frequency : number of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] frequency

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Skin conductance responses \[SCR\] frequency : number of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] frequency

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** Skin conductance responses \[SCR\] frequency : number of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] frequency

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] amplitude

**Time Frame:** Day 1 (V1)

**Description:** Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] amplitude

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] amplitude

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] amplitude

**Time Frame:** Up to 180 days from V1 (V4)

**Description:** Skin conductance responses amplitude: amplitude of the spontaneous galvanic skin responses by periods. SCR will be measured using the Galvanic skin responses \[GSR\]: GSR data will be recorded using 2 skin sensors placed on the third phalanx of the forefinger and of the middle finger of the left hand. Physiological data recorded are related to the cholinergic sympathetic activity (tonic GSR / phasic GSR).

**Measure:** Skin conductance responses [SCR] amplitude

**Time Frame:** Up to 360 days from V1 (V5)

**Description:** Delta frequency 0-4 Hertz band

Delta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Delta frequency (0-4Hz)

**Time Frame:** Day 1 (V1)

**Description:** Delta frequency 0-4 Hertz band

Delta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Delta frequency (0-4Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Delta frequency 0-4 Hertz band

Delta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Delta frequency (0-4Hz)

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Theta frequency 4-7 Hertz band

Theta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Theta frequency (4-7Hz)

**Time Frame:** Day 1 (V1)

**Description:** Theta frequency 4-7 Hertz band

Theta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Theta frequency (4-7Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Theta frequency 4-7 Hertz band

Theta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Theta frequency (4-7Hz)

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Alpha frequency 8-12 Hertz band Alpha frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Alpha frequency (8-12Hz)

**Time Frame:** Day 1 (V1)

**Description:** Alpha frequency 8-12 Hertz band Alpha frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Alpha frequency (8-12Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Alpha frequency 8-12 Hertz band Alpha frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Alpha frequency (8-12Hz)

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Beta frequency 13-30 Hertz band Beta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Beta frequency (13-30Hz)

**Time Frame:** Day 1 (V1)

**Description:** Beta frequency 13-30 Hertz band Beta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Beta frequency (13-30Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Beta frequency 13-30 Hertz band Beta frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Beta frequency (13-30Hz)

**Time Frame:** Up to 80 days from V1 (V3)

**Description:** Gamma frequency \>30 Hertz band

Gamma frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Gamma frequency (>30Hz)

**Time Frame:** Day 1 (V1)

**Description:** Gamma frequency \>30 Hertz band

Gamma frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Gamma frequency (>30Hz)

**Time Frame:** Up to 40 days from V1 (V2)

**Description:** Gamma frequency \>30 Hertz band

Gamma frequency will be measured using the electroencephalogram \[EEG\]: EEG data will be recorded using a EEG headsets including 128 electrodes. The EEG is related to the brain activity generated by the neural functioning.

**Measure:** Gamma frequency (>30Hz)

**Time Frame:** Up to 80 days from V1 (V3)

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Functional Neurological Disorders (FND) diagnosis must be medically established
* Participants must have a smartphone (android ou Iphone)
* Participants must be of the age of majority
* Participants must have signed an informed consent
* Sufficiently fluent in French to understand study documents and instructions
* Consistency in performing repeated questionnaires
* Normal or corrected-to-normal visual acuity

Exclusion Criteria:

* Specially protected participants: juveniles, pregnant womens, nursing mothers, law's protection peoples
* Participants suffering from a severe psychiatric disease needing specialised attention
* History of severe neurosurgical pathology
* Alcohol dependence or drug use
* Participants suffering from or have suffered from a severe disease causing autonomic dysfunctions (heart failure, asthma, blood disease, renal failure, peripheral neuropathy, vagotomy, thyroid disorder, alcoholism, liver disease, amyloidosis)
* Participants taking medication which could be impact autonomic nervous system activity (anticholinergic, antiarrhythmics, clonidine, beta-blockers, tricyclic anti-depressants, metronidazole)
* Participants placing under judicial or administrative supervisions

**Maximum Age:** 70 Years

**Minimum Age:** 18 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** jasmine.carlier.chum@ssss.gouv.qc.ca

**Name:** Jasmine Carlier, PhD student

**Phone:** (+33)680891913

**Role:** CONTACT

**Contact 2:**

**Email:** d.nguyen@umontreal.ca

**Name:** Dang Khoa Nguyen, Pr

**Phone:** 514-890-8000

**Phone Ext:** 28404

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Montréal

**Contacts:**

***Contact 1:***

- **Email:** jasmine.rachel.zoe.carlier@umontreal.ca

- **Name:** Jasmine Carlier, MD

- **Phone:** (+33)680891913

- **Role:** CONTACT

***Contact 2:***

- **Email:** d.nguyen@umontreal.ca

- **Name:** Dang Khoa Nguyen, Md, PhD, Pr

- **Phone:** H2X 0C1

- **Phone Ext:** 28404

- **Role:** CONTACT

***Contact 3:***

- **Name:** Dang Khoa Nguyen, Pr

- **Role:** PRINCIPAL_INVESTIGATOR

***Contact 4:***

- **Name:** Pascal Hot, Pr

- **Role:** SUB_INVESTIGATOR

**Country:** Canada

**Facility:** Université de Montréal's affiliated Hospital Research Centre (CRCHUM)

**State:** Quebec

**Zip:** H2X 0C1

#### Overall Officials

**Official 1:**

**Affiliation:** Université de Montréal's affiliated hospital research centre

**Name:** Dang Khoa Nguyen

**Role:** PRINCIPAL_INVESTIGATOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

### References Module

#### References

**Citation:** Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996 Mar 1;93(5):1043-65. No abstract available.

**PMID:** 8598068

**Citation:** Lehrer P, Kaur K, Sharma A, Shah K, Huseby R, Bhavsar J, Sgobba P, Zhang Y. Heart Rate Variability Biofeedback Improves Emotional and Physical Health and Performance: A Systematic Review and Meta Analysis. Appl Psychophysiol Biofeedback. 2020 Sep;45(3):109-129. doi: 10.1007/s10484-020-09466-z. Erratum In: Appl Psychophysiol Biofeedback. 2021 Dec;46(4):389.

**PMID:** 32385728

**Citation:** Laborde S, Mosley E, Thayer JF. Heart Rate Variability and Cardiac Vagal Tone in Psychophysiological Research - Recommendations for Experiment Planning, Data Analysis, and Data Reporting. Front Psychol. 2017 Feb 20;8:213. doi: 10.3389/fpsyg.2017.00213. eCollection 2017.

**PMID:** 28265249

**Citation:** Pick S, Anderson DG, Asadi-Pooya AA, Aybek S, Baslet G, Bloem BR, Bradley-Westguard A, Brown RJ, Carson AJ, Chalder T, Damianova M, David AS, Edwards MJ, Epstein SA, Espay AJ, Garcin B, Goldstein LH, Hallett M, Jankovic J, Joyce EM, Kanaan RA, Keynejad RC, Kozlowska K, LaFaver K, LaFrance WC Jr, Lang AE, Lehn A, Lidstone S, Maurer CW, Mildon B, Morgante F, Myers L, Nicholson C, Nielsen G, Perez DL, Popkirov S, Reuber M, Rommelfanger KS, Schwingenshuh P, Serranova T, Shotbolt P, Stebbins GT, Stone J, Tijssen MA, Tinazzi M, Nicholson TR. Outcome measurement in functional neurological disorder: a systematic review and recommendations. J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):638-649. doi: 10.1136/jnnp-2019-322180. Epub 2020 Feb 28.

**PMID:** 32111637

**Citation:** Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007 Jul;4(7):28-37.

**PMID:** 20526405

**Citation:** Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002 Mar-Apr;64(2):258-66. doi: 10.1097/00006842-200203000-00008.

**PMID:** 11914441

**Citation:** Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989 May;28(2):193-213. doi: 10.1016/0165-1781(89)90047-4.

**PMID:** 2748771

**Citation:** Steinberg M, Rounsaville B, Cicchetti D. Detection of dissociative disorders in psychiatric patients by a screening instrument and a structured diagnostic interview. Am J Psychiatry. 1991 Aug;148(8):1050-4. doi: 10.1176/ajp.148.8.1050.

**PMID:** 1853955

**Citation:** Loas G, Otmani O, Verrier A, Fremaux D, Marchand MP. Factor analysis of the French version of the 20-Item Toronto Alexithymia Scale (TAS-20). Psychopathology. 1996;29(2):139-44. doi: 10.1159/000284983.

**PMID:** 8861519

**Citation:** Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063.

**PMID:** 3397865

**Citation:** Boucsein W, Fowles DC, Grimnes S, Ben-Shakhar G, roth WT, Dawson ME, Filion DL; Society for Psychophysiological Research Ad Hoc Committee on Electrodermal Measures. Publication recommendations for electrodermal measurements. Psychophysiology. 2012 Aug;49(8):1017-34. doi: 10.1111/j.1469-8986.2012.01384.x. Epub 2012 Jun 8.

**PMID:** 22680988

**Citation:** American Clinical Neurophysiology Society. Guideline 6: A proposal for standard montages to be used in clinical EEG. J Clin Neurophysiol. 2006 Apr;23(2):111-7. doi: 10.1097/00004691-200604000-00007. No abstract available.

**PMID:** 16612227

#### See Also Links

**Label:** Radloff LS. The CES-D scale: a self report depression scale for research in the general population. App Psycho Meas 1977;1:384-401.

**URL:** http://conservancy.umn.edu/handle/11299/98561

**Label:** Paul Lehrer. Protocol for Heart Rate Variability Biofeedback Training. DOI:10.5298/1081-5937-41.3.08

**URL:** http://www.researchgate.net/publication/289937389_Protocol_for_Heart_Rate_Variability_Biofeedback_Training

**Label:** Alain Leplège 2001. Le questionnaire MOS SF-36, manuel d'utilisation et guide d'interprétation des scores

**URL:** http://www.researchgate.net/publication/281433197_Le_questionnaire_MOS_SF-36_manuel_d'utilisation_et_guide_d'interpretation_des_scores_French

**Label:** Kathi Baron 2006 A User's Manual for the Occupational Self Assessment (OSA) : (Version 2.2)

**URL:** http://search.worldcat.org/fr/title/A-User%27s-Manual-for-the-Occupational-Self-Assessment-(OSA)-:-(Version-2.2)/oclc/475547618

**Label:** C Demoulin 2017. Traduction en français du " Brief Illness Perceived Questionnaire " adapté aux patients lombalgiques et étude de ses qualités métrologiques. Doi : 10.1016/S1169-8330(16)30511-7

**URL:** http://www.em-consulte.com/article/1100188/traduction-en-francais-du-%C2%A0brief-illness-perceived

**Label:** Daniel Paquette 2004. Validation de la version française du CTQ et prévalence de l'histoire de maltraitance. DOI: 10.7202/008831ar

**URL:** http://www.erudit.org/fr/revues/smq/2004-v29-n1-smq755/008831ar/

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000013001

- Term: Somatoform Disorders

- ID: D000001523

- Term: Mental Disorders

- ID: D000006677

- Term: Histrionic Personality Disorder

- ID: D000010554

- Term: Personality Disorders

### Condition Browse Module - Browse Branches

- Abbrev: BXM

- Name: Behaviors and Mental Disorders

- Abbrev: All

- Name: All Conditions

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M6515

- Name: Conversion Disorder

- Relevance: HIGH

- As Found: Functional Neurological Disorder

- ID: M10096

- Name: Hysteria

- Relevance: HIGH

- As Found: Functional Neurological Disorder

- ID: M7394

- Name: Dissociative Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M15803

- Name: Somatoform Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M4815

- Name: Mental Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M14473

- Name: Psychotic Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M13462

- Name: Personality Disorders

- Relevance: LOW

- As Found: Unknown

- ID: T1568

- Name: Conversion Disorder

- Relevance: HIGH

- As Found: Functional Neurological Disorder

### Condition Browse Module - Meshes

- ID: D000009422

- Term: Nervous System Diseases

- ID: D000003291

- Term: Conversion Disorder

- ID: D000007046

- Term: Hysteria

### Misc Info Module

- Version Holder: 2024-05-31
